Persson A V, Padberg F T, Dyer V E
Compr Ther. 1980 Nov;6(11):12-7.
Fibrinolytic therapy is a useful addition to the armamentarium of most clinicians. Patients with fibrin-based intraluminal clots are seen by almost all physicians. With proper patient selection and careful physician adherence to dosage schedule and monitoring, the incidence of significant complications with fibrinolytic agents is about the same as with heparin therapy. Heparin stops the thrombotic process, whereas fibrinolytic therapy not only stops the thrombotic process, but often reestablishes a normal, hemodynamic state. Patients who undergo fibrinolytic therapy are spared long-term problems like amputation and the postphlebitic syndrome.
纤维蛋白溶解疗法是大多数临床医生治疗手段中的一项有用补充。几乎所有医生都会接诊患有纤维蛋白性腔内血栓的患者。通过适当的患者选择以及医生严格遵守给药方案和监测，纤维蛋白溶解剂严重并发症的发生率与肝素治疗大致相同。肝素可阻止血栓形成过程，而纤维蛋白溶解疗法不仅能阻止血栓形成过程，还常常能恢复正常的血流动力学状态。接受纤维蛋白溶解疗法的患者可避免截肢和血栓形成后综合征等长期问题。
